Impact of Concordance Between Antinuclear Antibody Indirect Immunofluorescence Patterns and Myositis Antibodies in Idiopathic Inflammatory Myopathies: Study Protocol
DOI:
https://doi.org/10.20344/amp.23542Keywords:
Antibodies, Antinuclear, Fluorescent Antibody Technique, Indirect, Immunoblotting, MyositisAbstract
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoimmune rheumatic disorders in which chronic inflammation of skeletal muscle leads to muscle weakness. Many other organs, including the skin, heart, lungs, and joints, may be affected. Patients with IIM may be positive for myositis antibodies (MAs), including myositis-specific and/or associated antibodies. Although helpful for establishing the diagnosis of IIM in the appropriate clinical setting, the presence of MAs does not always predict the occurrence of connective tissue diseases. Additionally, commonly used techniques such as line blot are known to have high rates of false positivity, especially for rare MAs. The accuracy of MAs tests such as line blot may be improved by cross-checking their results with antinuclear antibody (ANA) patterns on HEp-2 indirect immunofluorescence (IIF). This study aims to examine the concordance between ANA IIF patterns and myositis-specific antibodies in a Portuguese cohort of patients with IIM. We will assess whether concordance between methods is associated with increased fulfillment of IIM classification criteria, greater disease severity, or distinct patterns of organ involvement among affected patients.
Downloads
References
Dourado E, Bottazzi F, Cardelli C, Conticini E, Schmidt J, Cavagna L, et al. Idiopathic inflammatory myopathies: one year in review 2022. Clin Exp Rheumatol. 2023;41:199-213.
Liu Y, Zheng Y, Hao H, Yuan Y. Narrative review of autoantibodies in idiopathic inflammatory myopathies. Ann Transl Med. 2023;11:291.
Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7:87.
Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48-55.
Harvey GR, MacFadyen C, Tansley SL. Newer autoantibodies and laboratory assessments in myositis. Curr Rheumatol Rep. 2024;27:5.
van Dooren SH, van Venrooij WJ, Pruijn GJ. Myositis-specific autoantibodies: detection and clinical associations. Auto Immun Highlights. 2011;2:5-20.
Chan EK, von Mühlen CA, Fritzler MJ, Damoiseaux J, Infantino M, Klotz W, et al. The International Consensus on ANA Patterns (ICAP) in 2021-The 6th workshop and current perspectives. J Appl Lab Med. 2022;7:322-30.
Schumacher F, Zimmermann M, Kanbach M, Schulze W, Wollsching-Strobel M, Kroppen D, et al. Clinical relevance of positively determined myositis antibodies in rheumatology: a retrospective monocentric analysis. Arthritis Res Ther. 2024;26:132.
Loganathan A, Zanframundo G, Yoshida A, Faghihi-Kashani S, Bauer Ventura I, Dourado E, et al. Agreement between local and central anti-synthetase antibodies detection: results from the classification criteria of anti-synthetase syndrome project biobank. Clin Exp Rheumatol. 2024;42:277-87.
Vulsteke JB, De Langhe E, Claeys KG, Dillaerts D, Poesen K, Lenaerts J, et al. Detection of myositis-specific antibodies. Ann Rheum Dis. 2019;78:e7-10.
Infantino M, Tampoia M, Fabris M, Alessio MG, Previtali G, Pesce G, et al. Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis. Rheumatology. 2019;58:1239-44.
He J, Wei X, Sturgess A. Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort. Rheumatology. 2022;61:3792-8.
Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955-64.
Reuma.pt (Registo Nacional de Doentes Reumáticos). Área dos médicos. [cited 2025 Oct 02]. Available from: https://app.reuma.pt/reuma/Login.aspx?tipoBD=&lang=pt_PT.
Dourado E, Melo AT, Campanilho-Marques R, Bandeira M, Martins P, Fraga V, et al. The idiopathic inflammatory myopathies module of the Rheumatic Diseases Portuguese Register. ARP Rheumatol. 2023;2:188-99.
Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P. Bench to bedside review of myositis autoantibodies. Clin Mol Allergy. 2018;16:5.
Huang HL, Lin WC, Tsai WL, Weng CT, Weng MY, Wu CH, et al. Coexistence of multiple myositis-specific antibodies in patients with idiopathic inflammatory myopathies. J Clin Med. 2022;11:6972.
Stuhlmüller B, Schneider U, González-González JB, Feist E. Disease specific autoantibodies in idiopathic inflammatory myopathies. Front Neurol. 2019;10:438.
Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007;56:3132-7.
Alvarado-Cardenas M, Marin-Sánchez A, Martínez MA, Martínez-Martínez L, Pinal-Fernandez I, Labrador-Horrillo M, et al. Statin-associated autoimmune myopathy: a distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories. Autoimmun Rev. 2016;15:1161-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
